

REMARKS

Sequence Listing. Applicants submit herewith an electronic copy of the sequence listing in compliance with 37 C.F.R. § 1.821(e). No new matter has been added.

The amendments to the specification presented herein are made, *inter alia*, to insert the required sequence identifiers associated with various listed sequences.

Figure Legends. The Office alleges that Figure 14 contains a sequence labeled “ySIR2” that lacks a sequence identifier. As indicated in the amendments presented herein, the legend to Figure 14 has been amended to indicate that “ySIR2p” is also referred to as “ySIR2”, as used in the figure. No new matter has been added. Applicants submit that this amendment overcomes the objection.

The Office also alleges that Figure 19 contains a sequence identified as “mSIR2g” that lacks a sequence identifier. As indicated in the legend to Figure 19 at page 17, line 20 of the specification, “mSirg” is also referred to as “mSir2γ.” Thus, Applicants respectfully request that this objection be withdrawn, because the requisite sequence identifier is provided in the specification.

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicant hereby requests any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, please charge any deficiency to Deposit Account No. 50/2762.

Respectfully submitted,
Guarente et al., Applicant

By: /Natalie A. Lissy/
Natalie A. Lissy, Reg. No. 59,651
LOWRIE, LANDO & ANASTASI, LLP
One Main Street
Cambridge, Massachusetts 02142
United States of America
Telephone: 617-395-7000
Facsimile: 617-395-7070

Serial No.: 09/735,786

- 5 -

Art Unit: 1645

Date: May 19, 2008